Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 10, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at two upcoming in-person investor conferences.

CICC Healthcare Industry Forum 2023One-on-one & group meetings: May 17, 2023Location: Shanghai

Citi APAC Healthcare Conference 2023One-on-one & group meetings: May 18, 2023Location: Hong Kong

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CART™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

Media contact
Marvin Tang
[email protected]

Investor contact
Gracie Tong
[email protected]

You May Also Be Interested In

• PWP.BET Releases Unified Operator Console Combining Casino, Sportsbook and Compliance Tools in One System
• Lanny Davis Cites Possible Decision by Yosemite Park Service Staff for Favorable Environmental Reasons To Reduce Auto Pollution a Minor Land Swap With No Effect on Yosemite Parklands
• New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 2026